RheaVita has developed a continuous, controlled freeze-drying technology that integrates all the traditional freeze-drying process steps into one continuous production line.
By spinning the glass vials during the freezing process, a thin layer of product coats the inner lining of the vial. Following drying, the final solid freeze-dried product is obtained. Compared to the traditional freeze-drying process, RheaVita’s approach has several advantages, including very fast product and process development with limited experimental efforts, avoiding scale-up issues, reducing cycle times, lower production costs, less clean room space requirements, improving quality assurance and improved and uniform product quality and process uniformity.
By spinning the glass vials during the freezing process, a thin layer of product coats the inner lining of the vial. Following drying, the final solid freeze-dried product is obtained. Compared to the traditional freeze-drying process, RheaVita’s approach has several advantages, including very fast product and process development with limited experimental efforts, avoiding scale-up issues, reducing cycle times, lower production costs, less clean room space requirements, improving quality assurance and improved and uniform product quality and process uniformity.
Employees: 11-50
Total raised: $3.05M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Novalis Bi... | noval.is |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.06.2021 | Series A | $3.05M | Novalis Bi... |
Mentions in press and media 4
| Date | Title | Description |
| 30.11.2024 | RheaVita Announces Strategic Partnership With IMA Life | Ghent, Belgium, 18 November 2024, RheaVita Announces Strategic Partnership With IMA Life, Part of the IMA Group, to Drive Further Technological Development and Commercial Growth. |
| 07.06.2021 | RheaVita Raises €2.5M in Series A Funding | RheaVita, a Ghent, Belgium-based provider of freeze-drying technology for biopharmaceutical products, raised €2.5M in Series A funding. The round was led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV). Concur... |
| 02.06.2021 | RheaVita : Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV | RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing. The round was co-led by Novalis Biotech Acceleration and Pa... |
| - | RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV |